PREVIOUS ISSUE NEXT ISSUE
September 2017 Default Cover Image
5 things you need to know about TFOS DEWS IIWith great anticipation, the updated report of the TFOS Dry Eye WorkShop (DEWS II) was released last week. The first DEWS report was released in 2007.
Separate emotion when addressing conflictI've been witness of late to a lot of workplace conflict. It is my nature to avoid conflict. I'm certain it’s because I dealt with a lifetime of workplace conflict when I was a supervisor in the coal mines.
Why ODs should add meibography to their practicesMeibomian gland imaging clearly has a role, yet most practitioners aren’t looking at meibomian glands at all.
Risks of falls in glaucoma patientsTaking note of a patient’s behavior can provide a multitude of clues on the patient’s current condition. Perhaps the most apparent observational feature would be a patient’s gait.
Managing presbyopia with evolving inlay technologyInnovation does not cease and nor should our ability to stay abreast of the latest surgical options for our patients. The ever-growing population of presbyopes is endless, and the desire to rid oneself of spectacles is unquenchable.
9 habits for multifocal contact lens fitting successWhether that’s true or not, you shouldn’t be intimidated by multifocal lens fitting.
Smart home technology creates independence for patients with disabilitiesThe smart home market is expected to reach $121.73 billion by 2022.3 With these speculations, even stores like Home Depot now have a separate smart home device section. It is estimated that by 2020, there will be over 26 billion connected devices.
Q&A: Darryl Glover, OD: Cofounder of Defocus Media grew up in the Triangle area, Raleigh-Durham, NC. I spent time in Orlando, came back to North Carolina for college and for optometry school I went to Pennsylvania School of Optometry in Philadelphia.
Using neurostimulation to treat dry eyeNeurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
8 tips to make the most of your event experienceHere’s my advice on making the absolute most out of every event.
PREVIOUS ISSUE NEXT ISSUE